Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

10 April 2006

Serum prolactin level in patients with multiple sclerosis: A case control study.

Mohammad H. Harirchian, Mohammad A. Sahraian, Afsaneh Shirani

Med Sci Monit 2006; 12(4): CR177-180 :: ID: 448906

Abstract

Background: Multiple sclerosis (MS) is the most common demyelinating disorderof the central nervous system and is considered to be multifactorial with an autoimmune component. Prolactin(PRL) is a neuroendocrine peptide with potent immunomodulatory properties. Hyperprolactinemia enhancesseveral autoimmune disorders and may play a role in the pathogenesis of MS. The aim of this study wasto compare serum PRL levels in MS patients with those of healthy controls. Material/Methods: There were43 patients with definite MS and 43 sex- and age-matched healthy controls. Conditions leading to a risein PRL, such as pregnancy, lactation, and specific underlying diseases and drugs, were excluded. PRLlevels were measured in fasting blood samples. For the MS group, disease duration and subtype, clinicalmanifestations, and expanded disability status scores (EDSS) were also recorded. Results: There wereno significant differences in serum PRL levels between the case and control groups in both women andmen (376.78+/-231.11 mIU/l in female patients with MS vs. 364.19+/-202.55 mIU/l in female controls, 266.00+/-200.83mIU/l in male patients with MS vs. 197.25+/-65.25 mIU/l in male controls). We also found no significantrelationship between PRL and disease activity, disease duration, and EDSS. Conclusions: Our findingsdo not support the hypothesis that MS patients are in a hyperprolactinemic state. However, further studiesin more homogenous MS subgroups are needed.

Keywords: Case-Control Studies, Hyperprolactinemia - complications, Models, Biological, Multiple Sclerosis - etiology, Multiple Sclerosis, Chronic Progressive - etiology, Multiple Sclerosis, Relapsing-Remitting - etiology, Prolactin - blood

Add Comment 0 Comments

Editorial

01 March 2024 : Editorial  

Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia

Dinah V. Parums

DOI: 10.12659/MSM.944204

Med Sci Monit 2024; 30:e944204

0:00

In Press

18 Mar 2024 : Clinical Research  

Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative Study

Med Sci Monit In Press; DOI: 10.12659/MSM.944136  

0:00

21 Feb 2024 : Clinical Research  

Potential Value of HSP90α in Prognosis of Triple-Negative Breast Cancer

Med Sci Monit In Press; DOI: 10.12659/MSM.943049  

22 Feb 2024 : Review article  

Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943168  

23 Feb 2024 : Clinical Research  

A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943732  

Most Viewed Current Articles

16 May 2023 : Clinical Research  

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

17 Jan 2024 : Review article  

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

14 Dec 2022 : Clinical Research  

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750